Publications by authors named "C Treceno Lobato"
Article Synopsis
- - The study involved screening around 2.5 million compounds from various databases to identify potential inhibitors of a chimeric tyrosine kinase, focusing on their antiproliferative activity and pharmacokinetic properties.
- - Nine compounds were identified as having desirable ADME/Tox properties, with their biological activity predictions indicating that they could be effective protein kinase inhibitors, showing varied activity percentages.
- - Two promising compounds, LMQC01 and LMQC04, demonstrated strong molecular docking results and stability in simulations, suggesting they have good potential for inhibiting the enzyme function of the target kinase and are easy to synthesize.
Background: Beyond carrying the plant embryo, seeds harbour intricate microbial communities whose transmission across successive plant generations can significantly influence the ecological and evolutionary dynamics of plant-microbe symbioses. The process of plant domestication has potential repercussions in genes involved in plant-microbiome interactions. However, the extent to which breeding can impact the seed microbiome is sparsely explored.
View Article and Find Full Text PDFBackground And Aims: Chronic hepatitis delta represents a major global health burden. Clinical features of hepatitis D virus (HDV) infection vary largely between different regions worldwide. Treatment approaches are dependent on the approval status of distinct drugs and financial resources.
View Article and Find Full Text PDFWe present a case of a case of a man in his 70s on multiple medications (including treatment of ischemic heart disease and diabetes who developed significant rhabdomyolysis, complicated by acute kidney injury (AKI) and encephalopathy, while using a compounded medication for weight loss. The patient was admitted to the intensive care unit and progressed favourably after haemodialysis and supportive care. Information regarding the ingestion of weight-loss drugs was unknown at the time of admission and was only discovered after resolution of encephalopathy, raising the possibility of toxin-associated rhabdomyolysis.
View Article and Find Full Text PDFArticle Synopsis
- Post-bariatric hypoglycaemia (PBH) is a problematic condition often seen after Roux-en-Y gastric bypass surgery, and current treatments like acarbose have limited effectiveness and side effects that affect patient compliance.
- This clinical trial aims to compare the effects of canagliflozin, a newer medication, against acarbose and a placebo on blood glucose levels in individuals with PBH.
- If canagliflozin proves effective and safe, it could offer a new treatment option for PBH and help uncover mechanisms related to the condition.